Elucid Raises $27M in Series B Funding

Elucid, a Boston, MA-company developing non-invasive medical software to characterize cardiovascular disease, raised $27M in Series B funding.

The round was led and participated by an unidentified strategic investor. Other investors included Biovision Ventures, IAG Capital and Bold Brain Ventures.

The company plans to use the funds for growth and development.

Elucid’s CEO Blake Richards is the founder and CEO. Elucid uses validated AI to provide doctors with a software platform that optimizes treatment decisions for patients suffering from cardiovascular disease. The FDA-Cleared and CE-marked non-invasive software quantifies atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core.

The machine learning algorithms can be used to characterize the tissue types found in the artery walls that are known to cause heart attacks.  The ability to detect complex plaque biology at the molecular, cellular, and cellular level is enabling new applications to derive fractional flow reserves (FFRct), risk for heart attack/stroke, expression prediction, and therapeutic selection.

This method allows physicians to diagnose chest pain and determine if patients have advanced-stage heart disease.

The software is available for commercial use in the U.S., Europe, and South Korea.

Get latest news from African Startup ecosystem

Latest stories

You might also like...